Kandesartan – od początku i na lata dla ochrony serca i mózgu Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
cze 20, 2022
Słowa kluczowe:
kandesartan, antagonista receptora angiotensynowego, nadciśnienie tętnicze, skuteczność hipotensyjna, zdarzenia niepożądane
##plugins.themes.bootstrap3.article.main##
Abstrakt
Kandesartan charakteryzuje się najwyższą spośród antagonistów receptora angiotensynowego selektywnością wobec receptorów AT1, wykazuje wysoką biodostępność i całodobowe działanie hipotensyjne. Skuteczność hipotensyjna kandesartanu została udowodniona u pacjentów z nadciśnieniem tętniczym od łagodnego stopnia do ciężkiego nadciśnienia, zarówno dla monoterapii, jak i skojarzeń kandesartanu z antagonistą wapnia lub diuretykiem. Kandesartan zgodnie z aktualnymi wytycznymi może być stosowany do rozpoczynania terapii przeciwnadciśnieniowej, zwłaszcza wobec dostępności jego połączeń z lekami hipotensyjnymi innych klas w postaci leku złożonego. Bezpieczeństwo i bardzo dobra tolerancja kandesartanu czynią go lekiem przydatnym do stosowania przez kolejne lata terapii, a udowodnione właściwości kardio- i neuroprotekcyjne pozwalają korzystnie wpływać na rokowanie sercowo-naczyniowe pacjentów.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Stolarz-Skrzypek , K. (2022). Kandesartan – od początku i na lata dla ochrony serca i mózgu . Medycyna Faktów , 15(2(55), 155-159. https://doi.org/10.24292/01.MF.0222.6
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Gleiter CH, Mörike KE. Clinical pharmacokinetics of candesartan. Clin Pharmacokinet. 2002; 41(1): 7-17.
2. Reif M, White WB, Fagan TC et al. Effects of candesartan cilexetil in patients with systemic hypertension. Am J Cardiol. 1998; 82: 961-5.
3. Fridman K, Andersson OK, Wysocki M et al. Effects of an acute dose of 16 mg candesartan cilexetil on systemic and renal haemodynamics in hypertensive patients. J Human Hypertens. 1997; 11(suppl 2): S43-S44.
4. Weisser B, Gerwe M, Braun M et al. Investigations of the antihypertensive long-term action of candesartan cilexetil in different dosages under the influence of therapy-free intervals. Arzneimittelforschung. 2005; 55(9): 505-13 [abstract].
5. Shimizu M, Ishikawa J, Yano Y et al. Association between asleep blood pressure and brain natriuretic peptide during antihypertensive treatment: the Japan Morning Surge-Target Organ Protection (J-TOP) study. J Hypertens. 2012; 30(5): 1015-21.
6. Minatoguchi S, Aoyama T, Kawai N et al. Comparative effect of candesartan and amlodipine, and effect of switching from valsartan, losartan, telmisartan and olmesartan to candesartan, on early morning hypertension and heart rate. Blood Press. 2013; 22(suppl 1): 29-37.
7. Lee HY, Hong BK, Chung WJ et al. Phase IV, 8-week, multicenter, randomized, active treatment-controlled, parallel group, efficacy, and tolerability study of high-dose candesartan cilexetil combined with hydrochlorothiazide in Korean adults with stage II hypertension. Clin Ther. 2011; 33(8): 1043-56.
8. Bönner G, Landers B, Bramlage P. Candesartan cilexetil/hydrochlorothiazide combination treatment versus high-dose candesartan cilexetil monotherapy in patients with mild to moderate cardiovascular risk (CHILI Triple T). Vasc Health Risk Manag. 2011; 7: 85-95.
9. Rakugi H, Ogihara T, Miyata Y. Evaluation of the efficacy and tolerability of combination therapy with candesartan cilexetil and amlodipine besilate compared with candesartan cilexetil monotherapy and amlodipine besilate monotherapy in Japanese patients with mild-to-moderate essential hypertension: a multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2012; 34(4): 838-48.
10. Belcher G, Hübner R, George M et al. Candesartan cilexetil: safety and tolerability in healthy volunteers and patients with hypertension. J Human Hypertens. 1997; 11(suppl 2): S85-S89.
11. Williams B, Mancia G, Spiering W et al. 2018 Practice Guidelines for the management of arterial hypertension of the European Society of Hypertension and the European Society of Cardiology: ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens. 2018; 36(12): 2284-309.
12. Kario K, Hoshide S, Shimizu M et al. Effect of dosing time of angiotensin II receptor blockade titrated by self-measured blood pressure recordings on cardiorenal protection in hypertensives: the Japan Morning Surge-Target Organ Protection (J-TOP) study. J Hypertens. 2010; 28(7): 1574-83.
13. Ogihara T, Nakao K, Fukui T et al. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial. Hypertension. 2008; 51(2): 393-8.
14. Ogihara T, Ueshima K, Nakao K et al. Long-term effects of candesartan and amlodipine on cardiovascular morbidity and mortality in Japanese high-risk hypertensive patients: the Candesartan Antihypertensive Survival Evaluation in Japan Extension Study (CASE-J Ex). Hypertens Res. 2011; 34(12): 1295-301.
15. Escobar C, Barrios V, Calderón A et al. Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in hypertensive patients with the metabolic syndrome: data from the SARA Study. J Clin Hypertens (Greenwich). 2008; 10(3): 208-14.
16. Cuspidi C, Muiesan ML, Valagussa L et al. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study. J Hypertens. 2002; 20(11): 2293-300.
17. Lithell H, Hansson L, Skoog I et al. SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE). Principal results of a randomised double-blind intervention trial. J Hypertens. 2003; 21: 875-86.
18. Saxby BK, Harrington F, Wesnes KA et al. Candesartan and cognitive decline in older patients with hypertension: a substudy of the SCOPE trial. Neurology. 2008; 70(19 Pt 2): 1858-66.
19. Tykarski A, Filipiak KJ, Januszewicz A. Zasady postępowania w nadciśnieniu tętniczym – 2019 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciśnienie Tętnicze w Praktyce. 2019; 5(1): 1-86.
20. Pfeffer MA, Swedberg K, Granger CB et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003; 362(9386): 759-66.
21. Ducharme A, Swedberg K, Pfeffer MA et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J. 2006; 152(1): 86-92.
2. Reif M, White WB, Fagan TC et al. Effects of candesartan cilexetil in patients with systemic hypertension. Am J Cardiol. 1998; 82: 961-5.
3. Fridman K, Andersson OK, Wysocki M et al. Effects of an acute dose of 16 mg candesartan cilexetil on systemic and renal haemodynamics in hypertensive patients. J Human Hypertens. 1997; 11(suppl 2): S43-S44.
4. Weisser B, Gerwe M, Braun M et al. Investigations of the antihypertensive long-term action of candesartan cilexetil in different dosages under the influence of therapy-free intervals. Arzneimittelforschung. 2005; 55(9): 505-13 [abstract].
5. Shimizu M, Ishikawa J, Yano Y et al. Association between asleep blood pressure and brain natriuretic peptide during antihypertensive treatment: the Japan Morning Surge-Target Organ Protection (J-TOP) study. J Hypertens. 2012; 30(5): 1015-21.
6. Minatoguchi S, Aoyama T, Kawai N et al. Comparative effect of candesartan and amlodipine, and effect of switching from valsartan, losartan, telmisartan and olmesartan to candesartan, on early morning hypertension and heart rate. Blood Press. 2013; 22(suppl 1): 29-37.
7. Lee HY, Hong BK, Chung WJ et al. Phase IV, 8-week, multicenter, randomized, active treatment-controlled, parallel group, efficacy, and tolerability study of high-dose candesartan cilexetil combined with hydrochlorothiazide in Korean adults with stage II hypertension. Clin Ther. 2011; 33(8): 1043-56.
8. Bönner G, Landers B, Bramlage P. Candesartan cilexetil/hydrochlorothiazide combination treatment versus high-dose candesartan cilexetil monotherapy in patients with mild to moderate cardiovascular risk (CHILI Triple T). Vasc Health Risk Manag. 2011; 7: 85-95.
9. Rakugi H, Ogihara T, Miyata Y. Evaluation of the efficacy and tolerability of combination therapy with candesartan cilexetil and amlodipine besilate compared with candesartan cilexetil monotherapy and amlodipine besilate monotherapy in Japanese patients with mild-to-moderate essential hypertension: a multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2012; 34(4): 838-48.
10. Belcher G, Hübner R, George M et al. Candesartan cilexetil: safety and tolerability in healthy volunteers and patients with hypertension. J Human Hypertens. 1997; 11(suppl 2): S85-S89.
11. Williams B, Mancia G, Spiering W et al. 2018 Practice Guidelines for the management of arterial hypertension of the European Society of Hypertension and the European Society of Cardiology: ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens. 2018; 36(12): 2284-309.
12. Kario K, Hoshide S, Shimizu M et al. Effect of dosing time of angiotensin II receptor blockade titrated by self-measured blood pressure recordings on cardiorenal protection in hypertensives: the Japan Morning Surge-Target Organ Protection (J-TOP) study. J Hypertens. 2010; 28(7): 1574-83.
13. Ogihara T, Nakao K, Fukui T et al. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial. Hypertension. 2008; 51(2): 393-8.
14. Ogihara T, Ueshima K, Nakao K et al. Long-term effects of candesartan and amlodipine on cardiovascular morbidity and mortality in Japanese high-risk hypertensive patients: the Candesartan Antihypertensive Survival Evaluation in Japan Extension Study (CASE-J Ex). Hypertens Res. 2011; 34(12): 1295-301.
15. Escobar C, Barrios V, Calderón A et al. Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in hypertensive patients with the metabolic syndrome: data from the SARA Study. J Clin Hypertens (Greenwich). 2008; 10(3): 208-14.
16. Cuspidi C, Muiesan ML, Valagussa L et al. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study. J Hypertens. 2002; 20(11): 2293-300.
17. Lithell H, Hansson L, Skoog I et al. SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE). Principal results of a randomised double-blind intervention trial. J Hypertens. 2003; 21: 875-86.
18. Saxby BK, Harrington F, Wesnes KA et al. Candesartan and cognitive decline in older patients with hypertension: a substudy of the SCOPE trial. Neurology. 2008; 70(19 Pt 2): 1858-66.
19. Tykarski A, Filipiak KJ, Januszewicz A. Zasady postępowania w nadciśnieniu tętniczym – 2019 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciśnienie Tętnicze w Praktyce. 2019; 5(1): 1-86.
20. Pfeffer MA, Swedberg K, Granger CB et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003; 362(9386): 759-66.
21. Ducharme A, Swedberg K, Pfeffer MA et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J. 2006; 152(1): 86-92.